

(Authority: Government in the Sunshine Act, 5 U.S.C. 552b)

Vicktoria J. Allen,

Deputy Secretary of the Commission.

[FR Doc. 2024–25018 Filed 10–23–24; 4:15 pm]

BILLING CODE 6715–01–P

FEDERAL RESERVE SYSTEM

Change in Bank Control Notices; Acquisitions of Shares of a Bank or Bank Holding Company

The notificants listed below have applied under the Change in Bank Control Act (Act) (12 U.S.C. 1817(j)) and § 225.41 of the Board's Regulation Y (12 CFR 225.41) to acquire shares of a bank or bank holding company. The factors that are considered in acting on the applications are set forth in paragraph 7 of the Act (12 U.S.C. 1817(j)(7)).

The public portions of the applications listed below, as well as other related filings required by the Board, if any, are available for immediate inspection at the Federal Reserve Bank(s) indicated below and at the offices of the Board of Governors. This information may also be obtained on an expedited basis, upon request, by contacting the appropriate Federal Reserve Bank and from the Board's Freedom of Information Office at <https://www.federalreserve.gov/foia/request.htm>. Interested persons may express their views in writing on the standards enumerated in paragraph 7 of the Act.

Comments received are subject to public disclosure. In general, comments received will be made available without change and will not be modified to remove personal or business information including confidential, contact, or other identifying information. Comments should not include any information such as confidential information that would not be appropriate for public disclosure.

Comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors, Ann E. Misback, Secretary of the Board, 20th Street and Constitution Avenue NW, Washington, DC 20551–0001, not later than November 12, 2024.

A. Federal Reserve Bank of Chicago (Colette A. Fried, Assistant Vice President) 230 South LaSalle Street, Chicago, Illinois 60690–1414.

Comments can also be sent electronically to

Comments.applications@chi.frb.org:

1. *The Deborah A. Talen Trust, Deborah A. Talen, as trustee, both of*

Minneapolis, Minnesota; to become a member of the Talen Family Control Group, a group acting in concert, to acquire voting shares of Talen, Inc., and thereby indirectly acquire voting shares of Farmers Savings Bank & Trust, both of Traer, Iowa.

B. Federal Reserve Bank of San Francisco (Joseph Cuenco, Assistant Vice President, Formations & Transactions) 101 Market Street, San Francisco, California 94105. Comments can also be sent electronically to sf.fisc.comments.applications@sf.frb.org:

1. *Russell S. Colombo, Walla Walla, Washington; to join Megan F. Clubb and Clifford W. Kontos, both of Walla Walla, Washington, a group acting in concert, to control voting shares of Baker Boyer Bancorp, and thereby indirectly control voting shares of Baker Boyer National Bank, both of Walla Walla, Washington.*

Board of Governors of the Federal Reserve System.

Michele Taylor Fennell,

Associate Secretary of the Board.

[FR Doc. 2024–24898 Filed 10–24–24; 8:45 am]

BILLING CODE P

FEDERAL TRADE COMMISSION

Senior Executive Service Performance Review Board

AGENCY: Federal Trade Commission (FTC).

ACTION: Notice.

SUMMARY: Notice is hereby given of the appointment of members to the FTC Performance Review Board.

FOR FURTHER INFORMATION CONTACT:

Tamika Williams, Acting Chief Human Capital Officer, 600 Pennsylvania Avenue NW, Washington, DC 20580, (202) 326–2184.

SUPPLEMENTARY INFORMATION:

Publication of the Performance Review Board (PRB) membership is required by 5 U.S.C. 4314(c)(4). The PRB reviews and evaluates the initial appraisal of a senior executive's performance by the supervisor, and makes recommendations regarding performance ratings, performance awards, and pay-for-performance pay adjustments to the Chair.

The following individuals have been designated to serve on the Commission's Performance Review Board:

Monique Fortenberry, Director, Office of Workplace Inclusivity & Opportunity
Robin Moore, Principal Deputy General Counsel

Maribeth Petrizzi, Assistant Director for Compliance, Bureau of Competition

David Robbins, Executive Director, PRB Chair

Ted Rosenbaum, Deputy Director for Research and Management, Bureau of Economics

Rebecca Unruh, Deputy Director, Bureau of Consumer Protection

Tamika Williams, Acting Chief Human Capital Officer

By direction of the Commission.

April J. Tabor,

Secretary.

[FR Doc. 2024–24904 Filed 10–24–24; 8:45 am]

BILLING CODE 6750–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[60Day–25–0612; Docket No. CDC–2024–0083]

Proposed Data Collection Submitted for Public Comment and Recommendations

AGENCY: Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

ACTION: Notice with comment period.

SUMMARY: The Centers for Disease Control and Prevention (CDC), as part of its continuing effort to reduce public burden and maximize the utility of government information, invites the general public and other federal agencies the opportunity to comment on a continuing information collection, as required by the Paperwork Reduction Act of 1995. This notice invites comment on a proposed information collection project titled Well-Integrated Screening and Evaluation for Women Across the Nation (WISEWOMAN) Reporting System. The WISEWOMAN program is designed to prevent, detect, and control, hypertension and other cardiovascular disease (CVD) risk factors through services such as health coaching, and evidence informed lifestyle programs, which are tailored for individual and group behavior change.

DATES: CDC must receive written comments on or before December 24, 2024.

ADDRESSES: You may submit comments, identified by Docket No. CDC–2024–0083 by of either the following methods:

- *Federal eRulemaking Portal:* www.regulations.gov. Follow the instructions for submitting comments.
- *Mail:* Jeffrey M. Zirger, Information Collection Review Office, Centers for

Disease Control and Prevention, 1600 Clifton Road NE, MS H21–8, Atlanta, Georgia 30329.

Instructions: All submissions received must include the agency name and Docket Number. CDC will post, without change, all relevant comments to www.regulations.gov.

Please note: Submit all comments through the Federal eRulemaking portal (www.regulations.gov) or by U.S. mail to the address listed above.

FOR FURTHER INFORMATION CONTACT: To request more information on the proposed project or to obtain a copy of the information collection plan and instruments, contact Jeffrey M. Zirger, Information Collection Review Office, Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS H21–8, Atlanta, Georgia 30329; Telephone: 404–639–7118; Email: omb@cdc.gov.

SUPPLEMENTARY INFORMATION: Under the Paperwork Reduction Act of 1995 (PRA) (44 U.S.C. 3501–3520), federal agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. In addition, the PRA also requires federal agencies to provide a 60-day notice in the **Federal Register** concerning each proposed collection of information, including each new proposed collection, each proposed extension of existing collection of information, and each reinstatement of previously approved information collection before submitting the collection to the OMB for approval. To comply with this requirement, we are publishing this notice of a proposed data collection as described below.

The OMB is particularly interested in comments that will help:

- 1. Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;
- 2. Evaluate the accuracy of the agency’s estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;
- 3. Enhance the quality, utility, and clarity of the information to be collected;
- 4. Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submissions of responses; and
- 5. Assess information collection costs.

Proposed Project

Well-Integrated Screening and Evaluation for Women Across the Nation (WISEWOMAN) Reporting System (OMB Control No. 0920–0612, Exp. 3/31/2025)—Revision—National Center for Chronic Disease and Prevention and Health Promotion (NCCDPHP), Centers for Disease Control and Prevention (CDC).

Background and Brief Description

The Well-Integrated Screening and Evaluation for Women Across the Nation (WISEWOMAN) program sponsored by the CDC, provides services to low income, uninsured, or underinsured women aged 35–64. The WISEWOMAN program is designed to prevent, detect, and control hypertension and other cardiovascular disease (CVD) risk factors through healthy behavior support services which are tailored for individual and group behavior change. The WISEWOMAN program provides services to participants who are jointly enrolled in the National Breast and Cervical Cancer Early Detection Program (NBCCEDP), which is also administered by CDC.

The WISEWOMAN program is administered by state health departments and tribal programs. In 2023, a new five-year cooperative agreement was awarded under Funding Opportunity Announcement DP23–0003, subject to the availability of funds. CDC collects two types of information from WISEWOMAN awardees. The WISEWOMAN awardee submits an electronic data file to CDC twice per year. The Minimum Data Elements

(MDE) file contains data using a unique identifier with client-level information about CVD risk factors and types of healthy behavior support services for participants served by the program. The estimated burden per response for the MDE file is 25 hours. The Annual Progress Report provides a narrative summary of each awardee’s objectives and the activities undertaken to meet program goals. The estimated burden per response is 16 hours.

The WISEWOMAN Program is requesting three additional years to continue data collection. The 2024 OMB Directive 15 for a combined race and ethnicity question will replace the separate race and ethnicity minimum data elements. Two MDEs are being deleted and two MDEs are being added, and a response option is being added to one MDE. There are no changes to overall burden. CDC will continue to use the information collected from WISEWOMAN awardees to support program monitoring and improvement activities, program assessment, and evaluation of program outcomes. The overall program evaluation helps to demonstrate program accomplishments and strengthen the evidence for strategy implementation for improved engagement of underserved populations. It can also determine whether the identified strategies and associated activities can be implemented at various levels within a state or tribal organization. The data collection is designed to demonstrate how WISEWOMAN can obtain CVD health outcome data on at-risk populations, promote public education about CVD risk-factors, and improve the availability of healthy behavior support services for under-served participants.

This is a Revision for the WISEWOMAN information collection (OMB Control No. 0920–0612, Exp. 03/31/2025). Participation in this information collection is required as a condition of cooperative agreement funding. There are no costs to respondents other than their time. The total estimated annual burden hours are 2,640.

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondents	Form name	Number of respondents	Number of responses per respondent	Average burden per response (in hrs.)	Total burden (in hrs.)
WISEWOMAN Awardees	Screening and Assessment and Lifestyle Program MDEs	40	2	25	2,000
	Annual Progress Report	40	1	16	640
Total					2,640

Jeffrey M. Zirger,

Lead, Information Collection Review Office,
Office of Scientific Integrity, Office of Science,
Centers for Disease Control and Prevention.

[FR Doc. 2024–24921 Filed 10–24–24; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[60Day–25–1385; Docket No. CDC–2024–
0084]

Proposed Data Collection Submitted for Public Comment and Recommendations

AGENCY: Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).

ACTION: Notice with comment period.

SUMMARY: The Centers for Disease
Control and Prevention (CDC), as part of
its continuing effort to reduce public
burden and maximize the utility of
government information, invites the
general public and other federal
agencies the opportunity to comment on
a continuing information collection, as
required by the Paperwork Reduction
Act of 1995. This notice invites
comment on a proposed information
collection project titled Characteristics
of Cases of Priority Fungal Diseases.
These case report forms (CRF) collect
information on patient demographics,
underlying conditions, diagnosis,
treatments, healthcare utilization, and
outcomes of patients with
coccidioidomycosis, histoplasmosis,
blastomycosis, *Candida auris*, triazole-
resistant *Aspergillus fumigatus* infection
or colonization, or antifungal-resistant
dermatophytosis, chromoblastomycosis,
mycetoma, and sporotrichosis.

DATES: CDC must receive written
comments on or before December 24,
2024.

ADDRESSES: You may submit comments,
identified by Docket No. CDC–2024–
0084 by either of the following methods:

- **Federal eRulemaking Portal:**
www.regulations.gov. Follow the
instructions for submitting comments.
- **Mail:** Jeffrey M. Zirger, Information
Collection Review Office, Centers for
Disease Control and Prevention, 1600
Clifton Road NE, MS H21–8, Atlanta,
Georgia 30329.

Instructions: All submissions received
must include the agency name and
Docket Number. CDC will post, without
change, all relevant comments to
www.regulations.gov.

Please note: Submit all comments
through the Federal eRulemaking portal
(www.regulations.gov) or by U.S. mail to
the address listed above.

FOR FURTHER INFORMATION CONTACT: To
request more information on the
proposed project or to obtain a copy of
the information collection plan and
instruments, contact Jeffrey M. Zirger,
Information Collection Review Office,
Centers for Disease Control and
Prevention, 1600 Clifton Road NE, MS
H21–8, Atlanta, Georgia 30329;
Telephone: 404–639–7570; Email: omb@cdc.gov.

SUPPLEMENTARY INFORMATION: Under the
Paperwork Reduction Act of 1995 (PRA)
(44 U.S.C. 3501–3520), federal agencies
must obtain approval from the Office of
Management and Budget (OMB) for each
collection of information they conduct
or sponsor. In addition, the PRA also
requires federal agencies to provide a
60-day notice in the **Federal Register**
concerning each proposed collection of
information, including each new
proposed collection, each proposed
extension of existing collection of
information, and each reinstatement of
previously approved information
collection before submitting the
collection to the OMB for approval. To
comply with this requirement, we are
publishing this notice of a proposed
data collection as described below.

The OMB is particularly interested in
comments that will help:

1. Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
2. Evaluate the accuracy of the
agency's estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
3. Enhance the quality, utility, and
clarity of the information to be
collected;
4. Minimize the burden of the
collection of information on those who
are to respond, including through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submissions
of responses; and
5. Assess information collection costs.

Proposed Project

Characteristics of Cases of Priority
Fungal Diseases (OMB Control No.
0920–1385, Exp. 4/30/2027)—
Revision—National Center for Emerging
and Zoonotic Infectious Diseases

(NCEZID), Centers for Disease Control
and Prevention (CDC).

Background and Brief Description

Fungal diseases cause substantial
illness, ranging from mild infection to
severe or life-threatening invasive
disease. They also constitute a
considerable financial burden on
patients and healthcare systems.
Awareness of fungal diseases is low,
and data collection has historically been
limited in size, scope, and coordination,
which has hindered our understanding
of these diseases. Detailed
epidemiologic and clinical data are
critical to inform appropriate public
health responses.

CDC plans to enhance surveillance of
high priority fungal diseases across the
United States to better characterize
factors such as disease burden,
geographic scope, patient risk factors,
health disparities, healthcare utilization,
outcomes, and emerging trends. This
project will serve as a Revision to the
information collection project
Characteristics of Cases of Priority
Fungal Diseases (OMB Control No.
0920–1385). The Revision will expand
the number of fungal diseases for which
data may be collected. In addition to
triazole-resistant *A. fumigatus*
infections, coccidioidomycosis,
histoplasmosis, blastomycosis, *C. auris*,
and antifungal-resistant
dermatophytosis, Case Report Forms
(CRF) have also been developed for
chromoblastomycosis, mycetoma, and
sporotrichosis.

CDC plans to use standardized CRFs
to collect public health surveillance
data for cases of these diseases regarding
demographics (*e.g.*, age, sex, race/
ethnicity, location of residence),
underlying medical conditions,
diagnosis (*e.g.*, clinical presentation,
laboratory testing), treatments, and
outcomes (*e.g.*, hospitalization, vital
status). The corresponding CRF would
be filled out voluntarily by state, local
or tribal health departments, federal
agencies, and members of the private
sector (*e.g.*, academic institutions), and
contains a section for medical chart
review and an optional supplemental
interview (including data on potential
occupational or environmental
exposures) of the patient or their
representative. Findings can help
identify populations at higher risk of
these diseases, detect emerging
epidemiologic trends, and guide
prevention and response efforts. They
can also help better focus public and
healthcare provider outreach, inform
efforts to contain or mitigate spread, and
influence health policy and research on
prevention and treatment.